



NON-SMALL CELL LUNG CANCER (NSCLC) OPTIMAL SEQUENCE OF CHEMOTHERAPY AND IMMUNOTHERAPY

ERMINIA MASSARELLI, MD, PHD


Associate Professor Department of Medical Oncology & Therapeutics Research Section Chief, Thoracic Oncology Disease Team City of Hope National Medical Center

Disclosures

- Advisory Board Ad Hoc Consultant for Janssen, Lilly, BMS, Sanofi, and Merck.
- On the Speakers Bureau for AstraZeneca, Lilly, and Merck.



PD-1/PD-L1 Pathway and Immunotherapy Targets



🛣 Cityof Hope.

Treatment Approvals in Resectable Versus Metastatic NSCLC without Driver Mutations

Resectable Disease Maintenance Adjuvant Adjuvant durvalumab after cisplatin doublet atezolizumab chemoradiation chemotherapy therapy 2005 2018 ? **Metastatic Disease** Carboplatin + Taxane + Pembrolizumab: Carboplatin + Nivolumab Carboplatin + Pembrolizumab. Carboplatin + Nivolumab + Atezolizumab Pemetrexed + Paclitaxel + Taxane + Ipilimumab +/-Pembrolizumab Bevacizumab + Atezolizumab Chemotherapy Atezolizumab 2015 2016 2017 2018 2019 2020

Cityof Hope.


IMpower010: Adjuvant Atezolizumab in Completely Resected Stage IB-IIIA NSCLC

Completely resected stage IB-IIIA NSCLC per UICC/AJCC v7

- Stage IB tumors ≥4 cm
- ECOG 0-1
- Lobectomy/pneumonectomy
- Tumor tissue for PD-L1 analysis

Stratification factors

- Male/female
- Stage (IB vs II vs IIIA)
- Histology
- PD-L1 tumor expression status^a: TC2/3 and any IC vs TC0/1 and IC2/3 vs TC0/1 and IC0/1



Primary endpoints

- Investigator-assessed DFS tested hierarchically:
 - PD-L1 TC ≥1% (per SP263) stage II-IIIA population
 - All-randomized stage II-IIIA population
 - ITT population (stage IB-IIIA)


Key secondary endpoints

- OS in ITT population
- DFS in PD-L1 TC ≥50% (per SP263) stage II-IIIA population
- 3-y and 5-y DFS in all 3 populations

Both arms included observation and regular scans for disease recurrence on the same schedule. ECOG, Eastern Cooperative Oncology Group; IC, tumor-infiltrating immune cells; ITT, intent to treat; TC, tumor cells. ^a Per SP142 assay.

3

IMpower010: DFS Analyses



BSC 228 212 186 169 160 151 142 135 117 97 80 59 38 21 14 7 6 4 3

3 BSC 440 412 366 331 314 292 277 263 230 182 146 102 71 35 22 10 8 4 3


tezolizumab 507 478 437 418 403 387 367 353 306 257 212 139 97 53 38 19 14 8 4 BSC 498 467 418 383 365 342 324 309 269 219 173 122 90 46 30 13 10 5 4

	Atezolizumab (n=248)	BSC (n=228)		Atezolizumab (n=442)	BSC (n=440)		Atezolizumab (n=507)	BSC (n=498)
Median DFS (95% CI), mo	NE (36.1, NE)	35.3 (29.0, NE)	Median DFS (95% CI), mo	42.3 (36.0, NE)	35.3 (30.4, 46.4)	Median DFS (95% CI), mo	NE (36.1, NE)	37.2 (31.6, NE)
Stratified HR (95% CI)	0.66 (0.5	50, 0.88)	Stratified HR (95% CI)	0.79 (0.64, 0.96)		Stratified HR (95% CI)	0.81 (0.6	67, 0.99)
P value⁵	0.004 ^c		<i>P</i> value⁵	0.02 ^c		P value ^b	0.0	4 ^d

Presented by Enriqueta Felipe at ESMO 2021 6


IMpower010: DFS by PD-L1 Status

All-randomised stage II-IIIA population (with and without known EGFR/ALK+ disease)



Clinical cutoff: 21 January 2021. a Per SP263 assay.

IMpower010: Overall Survival



- OS data were immature at this pre-planned DFS interim analysis
 - OS in the ITT population was not formally tested
 - A trend toward OS improvement with atezolizumab was seen in the PD-L1 TC ≥1% stage II-IIIA population

X City of Hope.


12

IMpower010: Safety Data

n (%)	Atezolizumab (n=495)	BSC (n=495)
Any-cause AE	459 (92.7)	350 (70.7)
Treatment-related AE	335 (67.7)	-
Grade 3-4 AE	108 (21.8)	57 (11.5)
Treatment-related grade 3-4 AE	53 (10.7)	-
Serious AE	87 (17.6)	42 (8.5)
Treatment-related serious AE	37 (7.5)	-
Grade 5 AE	8 (1.6) ^b	3 (0.6) ^c
Treatment-related grade 5 AE	4 (0.8)	-
AE leading to dose interruption of atezolizumab	142 (28.7)	-
AE leading to atezolizumab discontinuation	90 (18.2)	-
Immune-mediated AEs	256 (51.7)	47 (9.5)
Grade 3-4 immune-mediated AEs	39 (7.9)	3 (0.6)
Immune-mediated AEs requiring the use of systemic corticosteroids	60 (12.1)	4 (0.8)

The safety profile was consistent with prior experience of atezolizumab monotherapy across indications and lines of therapy

CheckMate 816: Neoadjuvant Nivolumab + Platinum-Doublet Chemotherapy Versus Chemotherapy




Database lock: September 16, 2020; minimum follow-up: 7.6 months for NIVO + chemo and chemo arms.

aNCT02998528; this study included an exploratory arm: NIVO 3 mg/kg Q2W (3 cycles) + ipilimumab 1 mg/kg (cycle 1 only). Data from this arm are not included in this presentation; ^bDetermined by the PD-L1 IHC 28-8 pharmDx assay (Dako); ^cIncluded patients with PD-L1 expression status not evaluable and indeterminate; ^dNSQ: pemetrexed + cisplatin or paclitaxel + carboplatin; SQ: gemcitabine + cisplatin or paclitaxel + carboplatin; ^cVinorelbine + cisplatin, docetaxel + cisplatin, gemcitabine + cisplatin (SQ only), pemetrexed + cisplatin (NSQ only), or paclitaxel + carboplatin. 1. Forde PM, et al. Oral presentation at the AACR Annual Meeting; April 8-10, 2021; virtual. Abstract 5218.

3

CheckMate 816: Response





• pCR improvement with NIVO + chemo vs chemo was observed regardless of radiologic down-staging^d

^aPer BIPR in the ITT population; neither of the 2 patients with stage IV disease (1 in each arm) achieved pCR; ^b95% CI: NIVO + chemo, chemo (stage): 12.2-73.8, 0.0-36.9 (IB); 9.9-42.3, 0.1-16.2 (IIA); 9.4-45.1, 1.1-28.0 (IIB); 15.6-31.9, 0.0-4.7 (IIIA); ^cBaseline stage of disease by CRF, TNM 7th edition used for classification; ^dpCR rate in patients with radiographic down-staging: 31% with NIVO + chemo vs 7% with chemo; pCR rate in patients with radiographic down-staging: 22% with NIVO + chemo vs 1% with chemo.

> Nivo + chemo significantly improved pCR rates and had greater depth of pathologic response


NEOSTAR: Neoadjuvant Nivolumab versus Nivolumab + Ipilimumab in Locally Advanced NSCLC







- Compared with nivolumab, nivolumab + ipilimumab resulted in higher pathologic complete response rates (10% versus 38%) and less viable tumor (median 50% versus 9%)
- Neoadjuvant nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates, and immunologic memory

PACIFIC: Durvalumab after Chemoradiotherapy in Stage III NSCLC 5-Year Survival Update





City of Hope.




- In the PACIFIC trial, durvalumab after concurrent chemoradiation therapy significantly improved OS and PFS
- Updated 5-year results demonstrate sustained OS and PFS benefit
- The COAST trial is investigating durvalumab in combination with novel agents after concurrent chemoradiation in Stage III NSCLC


Immuno-Oncology Trials in Resectable NSCLC

Trial	NCT	Drug	Stage	Phase	Endpoint
IMpower 030	NCT03456063	CT + atezolizumab x 4 cycles \rightarrow S \rightarrow atezolizumab/placebo x 16 cycles	II-IIIB (cT3N2)	III	MPR, EFS
AEGEAN	NCT03800134	CT + durvalumab x 3 cycles \rightarrow S \rightarrow durvalumab/placebo x 12 cycles	IIA-IIIB	III	MPR
CheckMate 816	NCT02998528	CT + nivolumab x 3 cycles \rightarrow S cs CT x 3 cycles \rightarrow S	IB-IIIA	III	EFS, pCR
KEYNOTE 617	NCT03425643	CT + pembrolizumab x 4 cycles → S → pembrolizumab/placebo x 13 cycles	II-IIIB (cT3-4N2)	III	EFS, OS
SAKK 16/14	NCT02572843	CT x 3 → durvalumab x 2 cycles → S → durvalumab x 1 year	IIIA (N2)	II	EFS
PRICNEPS	NCT02994576	Atezolizumab x 1 cycles \rightarrow S	IB-IIIA (no N2)	II	Toxicity
MK3475-223	NCT02938624	Pembrolizumab different dose/regimens \rightarrow S	1-11	I	Toxicity, MPR
PEARLS	NCT02504372	S with or without CT → pembrolizumab/placebo	IB-IIIA	III	DFS
ANVIL	NCT02595944	S with or without CT \rightarrow nivolumab vs observation	IB-IIIA	III	DFS, OS
KEYNOTE 671	NCT03425643	Pembrolizumab + platinum doublet chemotherapy \rightarrow S	II-IIIB (T3-4N2)	III	EFS, OS


CT, adjuvant chemotherapy; DFS, disease-free survival; OS, overall survival; EFS, event free survival; MPR, major pathological response; pCR, pathological complete response; S, surgery.

Current First-Line Treatment in Metastatic NSCLC





CheckMate 227 3 Year Update: Study Design




Minimum Follow-Up for OS: 37.7 months

CheckMate 227 3 Year Update: Overall Survival

PD-L1 ≥ 1%






Minimum Follow-Up for OS: 37.7 months



CheckMate 227 3 Year Update: Post-Landmark Overall Survival Analysis in Responders at 6 Months



➤ Among patients with PD-L1≥1%, 70% of responders at 6 months in NIVO+IPI arm were alive 3 years later vs. 39% in chemo arm.

Similar findings were found in patients with PD-L1<1%.</p>


CheckMate 227 3 Year Update: Safety Summary

	All randor	nized (PD-L1	≥ 1% and PD)-L1 < 1%)	PD-L1	≥ 1%	PD-L1 < 1%		
		+ IPI 576)	Chemo (n = 570)			VO 391)	NIVO + chemo (n = 172)		
TRAE,ª %	Any grade	Grade 3-4	Any grade	Grade 3-4	Any grade	Grade 3-4	Any grade	Grade 3-4	
Any TRAE	77	33	82	36	66	20	92	56	
TRAEs leading to discontinuation of any component of the regimen	18	12	9	5	12	7	14	8	
Treatment-related deaths ^b	1		1		< 1		2		

Minimum Safety Follow-Up: 36.3 months



CheckMate 9LA: Study Design



K Cityof Hope.

CheckMate 9LA: Patient Characteristics and Duration of Therapy

	NIVO + IPI + chemo (n = 361)	Chemo (n = 358)		NIVO + IPI + chemo (n = 358)	Chemo (n = 349)
Age, median (range), years	65 (35-81)	65 (26-86)	Duration of therapy, median (range), mo	6.1 (0-23.5)	2.4 (0-24.0
Female, %	30	30	Number of doses, median (range)		
ECOG PS,ª %	31	31	NIVO IPI	9.0 (1-34) 4.0 (1-17)	Not applica
1	68	68	Treatment discontinuation, n (%)		N. 6
Smoking status, %	12	14	IPI NIVO + IPI	19ª (5) 265 (74)	Not applical
Never smoker Current / former smoker	13 87	14 86	Cycles of chemotherapy received, n (%)	25 (7)	23 (7)
Histology, % Squamous	31	31		333 (93) Not applicable	49 (14) 17 (5)
Non-squamous	69	69		Not applicable	260 (74)
Metastases, %			Patients receiving pemetrexed maintenance therapy, n (%)	Not applicable	158 ^b (45)
Bone Liver	27 19	31 24	Patients still on treatment, n (%)	74 (21)	28 (8)
CNS	18	16		·	
Tumor PD-L1 expression, ^b %			—		
< 1% ^c	40	39			
≥ 1% ^c	60	61			
1-49% ^c	38 22	32 29			
≥ 50% ^c		29			

🛣 Cityof Hope.


- Minimum follow-up 12.7 months.
- PFS and ORR were also significantly improved with Nivo + Ipi + chemotherapy versus chemotherapy.

											median OS, mo	mo		
										Subgroup	NIVO + IPI + chemo	Chemo	Unstratified HR	Unstratified HR (95% CI)
100							NIVO + I	PI + chemo	Chemo	Superoup	n = 361	n = 358		
100								= 361)	(n = 358)	All randomized (N = 719)	15.6	10.9	0.66ª	
	- Color				Medi	ian OS, mo		15.6	10.9	< 65 years (n = 354)	15.6	10.7	0.61	
00	and the second s	81%			(95%			9-20.0)	(9.5-12.6)	65 to < 75 years (n = 295)	19.4	11.9	0.62	
80 -						95% CI)		0.66 (0.55-0		≥ 75 years (n = 70)	8.5	11.5	1.21	
		- And				75% CT)		0.00 (0.55-0		Male (n = 504)	14.1	9.8	0.66	_ _
		200	-	63%						Female (n = 215)	19.4	15.8	0.68	
- 60 -		73%	De	-						ECOG PS 0 (n = 225)	NR	15.4	0.48	!
(%) SO		!	- Ala	1 7	and the second se					ECOG PS 1 (n = 492)	13.6	9.7	0.75	
S		1		-Gunger		And Addition of the			IPI + chemo	Never smoker (n = 98)	14.1	17.8	1.14	
° ₄₀ –		1		- COL	A Real Property					Smoker (n = 621)	15.6	10.4	0.62	i
40				47%						Squamous (n = 227)	14.5	9.1	0.62	
		i		1		Contraction of the local division of the loc			ch ch	Non-squamous (n = 492)	17.0	11.9	0.69	
20		1		1				CORDOCD-O-	- e o Chemo	Liver metastases (n = 154)	10.2	8.1	0.83	
20 -		1								No liver metastases (n = 565)	19.4	12.4	0.64	!
		1		i						Bone metastases (n = 207)	11.9	8.3	0.74	
		1		1						No bone metastases (n = 512)	20.5	12.4	0.65	
0 +		i	- 1					1		CNS metastases (n = 122)	NR	7.9	0.38	i
0	3	6	9	12	15	18	21	24	27	No CNS metastases (n = 597)	15.4	11.8	0.75	
•	5	0	,	Months	15	10	21	4 1		PD-L1 < 1% (n = 264)	16.8	9.8	0.62	
No. at risk	224			Months				10		PD-L1 ≥ 1% (n = 407)	15.8	10.9	0.64	
PI + chemo 361	326	292	250	227	153	86	33	10	1	PD-L1 1-49% (n = 233)	15.4	10.4	0.61	
Chemo 358	319	260	208	166	116	67	26	11	0	PD-L1 ≥ 50% (n = 174)	18.0	12.6	0.66	
									N	inimum follow-up: 12.7 months.			0.	125 0.25 0.5 1 2

Minimum follow-up: 12.7 months. *Stratified HR; unstratified HR was 0.67 (95% CI, 0.55-0.81). 0.125 0.25 0.5 1 2 NIVO + IPI + chemo


NIVO

CheckMate 9LA: Primary Endpoint Overall Survival by Histology



Minimum Follow-Up 12.7 months

CheckMate 9LA: Primary Endpoint Overall Survival by PD-L1 Status



Minimum Follow-Up 12.7 months


🛣 Cityof Hope.

Immuno-Oncology Clinical Trials in First-Line Metastatic NSCLC

Study	Selection	Design	PFS	OS
KN024 ¹	ADENO AND SCC PD-L1 > 50%	Pembro vs Chemo	10.3 vs 6.1 HR = 0.62	30 vs 14.2 HR = 0.63
KN042 ²	ADENO AND SCC PD-L1 > 1%	Pembro vs Chemo	7.1 vs 6.4 HR: 1.07	20 vs. 12 HR: 0.81
CHKMTE 227 ³	ADENO AND SCC PD-L1 > 1% PD-L1 < 1%	Ipilimumab + Nivo vs chemo	>1% HR 0.82 <1% HR 0.75	>1% 17.1 vs 14.9 HR: 0.79 <1% 17.2 vs 12.2 HR: 0.62
KN189 ⁴	ADENO PD-L1 0%-100%	Chemo/pembro vs chemo	8.8 vs 4.9 HR = 0.52	22 vs 11.3 HR = 0.49
IMpower150⁵	ADENO[Bev elig] PD-L1 0%-100%	Chemo/bev/atezo vs chemo/bev	8.3 vs 6.8 HR = 0.62	19.2 vs 14.7 HR = 0.78
KN4076	SCC PD-L1 0%-100%	Chemo/pembro vs chemo	6.4 vs 4.8 HR = 0.56	15.9 vs 11.3 HR = 0.64
IMpower130 ⁷	ADENO PD-L1 0%-100%	Nab-pacli/atezo vs chemo	7.0 vs 5.5 HR = 0.64	18.6 vs 13.9 HR = 0.79
Impower 110 ⁸	ADENO AND SCC PD-L1 > 50% (or IC >10%)	Atezolizumab v Chemo	8.1 vs 5.0 HR: 0.63	20.2 vs 13.1 HR 0.59

Conclusions

- Molecular predictors for response to immunotherapy are currently under validation in larger cohorts of metastatic NSCLC patients
- > Immunotherapy + chemotherapy combinations appear to be superior to monotherapy
- The ongoing phase III INSIGNA trial (NCT03793179) is investigating the approach to first-line immunotherapy + chemotherapy treatment and how to optimize treatment sequencing



CONTACT INFORMATION:

ERMINIA MASSARELLI, MD PHD

Associate Clinical Professor Department of Medical Oncology & Therapeutics Research Section Chief, Thoracic Oncology Disease Team City of Hope National Medical Center Email: emassarelli@coh.org

